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Abstract
Objectives: Muckle-Wells syndrome (MWS) is an autoinflammatory disease characterized by excessive interleukin-1
(IL-1) release, resulting in recurrent fevers, sensorineural hearing loss, and amyloidosis. IL-1 inhibition with anakinra,
an IL-1 receptor antagonist, improves clinical symptoms and inflammatory markers. Subclinical disease activity is
commonly observed. Canakinumab, a fully human IgG1 anti-IL-1b monoclonal antibody, can abolish excess IL-1b.
The study aim was to analyze the efficacy and safety of these two anti-IL-1 therapies.
Methods: Two cohorts of patients with severe MWS and confirmed NLRP3 mutation were treated with anakinra
and/or canakinumab. Clinical and laboratory features including ESR, CRP, SAA, and the neutrophil marker S100A12
were determined serially. Disease activity was captured by MWS disease activity scores (MWS-DAS). Remission was
defined as MWS-DAS ≤5 plus normal CRP and SAA. Treatment efficacy and safety were analyzed.
Results: The study included 12 anakinra- and 14 canakinumab-treated patients; the median age was 33.5 years (3.0
years to 72.0 years); 57% were female patients. Both treatment regimens led to a significant reduction of clinical
disease activity and inflammatory markers. At last follow-up, 75% of anakinra-treated and 93% of canakinumab-
treated patients achieved remission. During follow-up, S100A12 levels mirrored recurrence of disease activity. Both
treatment regimens had favorable safety profiles.
Conclusions: IL-1 blockade is an effective and safe treatment in MWS patients. MWS-DAS in combination with
MWS inflammatory markers provides an excellent monitoring tool set. Canakinumab led to a sustained control of
disease activity even after secondary failure of anakinra therapy. S100A12 may be a sensitive marker to detect
subclinical disease activity.
Keywords: NLRP3, CIAS1, mutation, Muckle-Wells syndrome, autoinflammatory fever syndromes, interleukin-1 inhibi-
tion, anakinra, canakinumab, S100A12
Introduction
Muckle-Wells syndrome (MWS) is an autoinflammatory
disease in the spectrum of inherited cryopyrin-associated
periodic syndromes (CAPS). CAPS comprise the mild
familial cold-induced autoinflammatory syndrome (FCAS),
the moderate MWS, and the severe neonatal-onset multi-
system inflammatory disease (NOMID), also known as
chronic infantile neurologic, cutaneous, articular (CINCA)
syndrome [1-3]. Most CAPS patients carry mutations in
the NLRP3 gene encoding the protein cryopyrin/NALP3
[4,5] which is essential for the activation of intracellular
caspase 1 and the processing of interleukin-1b (IL-1b)
[6-11]. Macrophages from MWS patients show a constitu-
tive increase of IL-1b [2,10,12,13].
Excessive production of IL-1b in MWS patients leads to
attacks of fever, rash, musculoskeletal symptoms, and con-
junctivitis. These characteristic features occur episodically
and can last between 1 day and 2 weeks. Musculoskeletal
symptoms include arthralgia, arthritis, and significant
myalgia. Urticarial rash and amyloidosis, together with
progressive sensorineural hearing loss, are clinical findings
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supporting the diagnosis of MWS [14]. Severe fatigue is
commonly found and has a significant impact on the qual-
ity of life of MWS patients. Sequelae of MWS include pro-
gressive sensorineural hearing loss, ultimately leading to
deafness, and renal amyloidosis.
Inflammatory markers, including C-reactive protein
(CRP) and the erythrocyte sedimentation rate (ESR), are
commonly elevated in patients with MWS, particularly
during acute inflammatory episodes [15]. Serum amyloid
A (SAA) is a marker of neutrophil activation and inflam-
mation. In patients with amyloidosis, SAA has been
reported to predict risk of mortality [16].
The neutrophil activation marker S100A12 (also named
EN-RAGE and calgranulin C) is secreted by granulocytes
[17], binds to the receptor for advanced glycation end pro-
ducts (RAGE), and shows a strong pro-inflammatory activ-
ity [17,18]. High S100A12 levels have been found in the
serum of active systemic juvenile idiopathic arthritis (sJIA)
and familial Mediterranean fever (FMF) patients [19-21].
Treatment of MWS patients targets IL-1. Studies sup-
ported the efficacy of IL-1 inhibition with either rilonacept,
a dimeric fusion protein consisting of the ligand-binding
domains of the extracellular portions of the IL-1 receptor
components (IL-1 TRAP) [22,23], canakinumab [24], or
anakinra [25]. Anakinra is a recombinant, soluble, nongly-
cosylated IL-1 receptor antagonist (IL-1Ra) [15,26-30] and
blocks the biologic activity of IL-1 by competitively binding
to the IL-1 type I receptor (IL-1RI) expressed on a wide
variety of tissues [31]. Anakinra therapy leads to symptom
control in patients with CAPS [26]. However, frequent
high-dose injections are not well tolerated [29,30]. Canaki-
numab, a fully human IgG1 anti-IL-1b monoclonal anti-
body, has been shown to provide selective and sustained
blockade of IL-1b, neutralizing the effect of excess IL-1b.
Canakinumab is reported to be well tolerated with no
infusion-related adverse events and no formation of anti-
canakinumab antibodies [24].
The aims of this study were (a) to report the clinical
and laboratory features of MWS patients requiring IL-1
blockade, (b) to determine the impact of IL-1 blockade
with either anakinra or canakinumab on clinical features
and laboratory markers, and (c) to analyze the efficacy




A single-center open-label, prospective observational study
of consecutive pediatric and adult patients diagnosed with
active MWS between April 2004 and August 2008 was
performed. All patients were treated with anakinra and/or
canakinumab. Informed individual consent was obtained
from all patients for NLRP3 mutation testing and for off-
label and experimental treatment. Approval from the local
ethics committee (Ethik Kommission der Medizinischen
Fakultät der Universität Tübingen) was obtained (REB no.
325/2007 BO1).
Patients
MWS patients were eligible if they met the following cri-
teria: (a) clinical features of active MWS requiring medical
intervention and (b) genetic confirmation of NLRP3 muta-
tion, as previously described [32]. Patients were excluded,
if they (a) were concurrently treated with other immune-
modulatory therapies such as methotrexate, (b) were
younger than 3 or older than 76 years of age at enroll-
ment, (c) had evidence of a preexisting underlying infec-
tion or significant medical conditions including heart
disease, recent infections, drug or alcohol abuse, or (d)
had received live vaccinations within the past 3 months.
Female patients of child-bearing age were required to start
an effective method of contraception.
Patients were followed according to a standardized
protocol in the institutional autoinflammatory clinics by
experienced pediatric and adult rheumatologists (JKD,
IK). Clinical and laboratory features and disease-activity
scores were collected from serial standardized assess-
ments obtained for all patients.
Data from some of the patients examined here have
been used in previous publications [24,30,32,33].
Anakinra cohort
Patients received anakinra (Kineret; Amgen, Cambridge,
UK) at a dose of 1 to 2 mg/kg/day in patients <40 kg body
weight and at a dose of 100 mg/day for those of ≥40 kg
body weight. The drug was self-administered by subcuta-
neous injection once daily. In children with persistent dis-
ease activity, the anakinra dose was stepwise escalated to a
maximum of 8 mg/kg. Concurrent nonsteroidal antiin-
flammatory medication was added, if required.
Canakinumab cohort
Patients were treated with canakinumab at a dose of
2 mg/kg SC for <40 kg body weight or 150 mg SC for
≥40 kg body weight every 8 weeks. In patients who did
not achieve remission by day 8, canakinumab was admi-
nistered at a dose of 5 mg/kg body weight intravenously.
Patients were allowed to switch anti-IL-1 therapy for lack
of efficacy or because of patient preference (roll-over).
On discontinuation of anakinra treatment, a disease flare
had to be awaited. The maximum wait time before the
start of canakinumab therapy for recurrence of disease
activity (flare) was limited to 14 days.
Demographics and clinical characteristics
Demographic information included gender, ethnicity, age
at diagnosis, age at onset of IL-1 blockade, and duration of
follow-up. Standardized assessments reviewed constitu-
tional symptoms of fever (pattern and duration) and fati-
gue and MWS organ manifestations, including headache,
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ocular symptoms including conjunctivitis, uveitis, papille-
dema, other eye symptoms, sensorineural hearing loss,
oral ulcers, abdominal pain, arthralgia, arthritis, myalgia,
and skin symptoms, including erythematous and cold-
induced rash. Associated conditions, disease complica-
tions, and sequelae, including hearing impairment or loss,
renal impairment, and delayed puberty, were recorded.
Muckle-Wells Syndrome Disease Activity Score
(MWS-DAS)
The previously developed MWS-DAS determines disease
activity in nine MWS domains attributing 0, 1, or 2
points to each level of disease activity [32]. MWS-DAS
captures (a) fever, (b) headache, (c) eye disease, (d) hear-
ing impairment, (e) oral ulcers, (f) abdominal pain, (g)
renal disease, (h) musculoskeletal disease, and (i) rash.
The tenth domain is the Patient Global Assessment
score measured on a visual analogue scale (VAS) and
categorized into 0 points for ≤1 cm, 1 point for >1 to
5 cm, and 2 points for strictly >5 to 10 cm. A MWS-
DAS of <10 points was considered mild disease activity.
Scores ≥10 points indicated severe MWS disease activ-
ity, as previously described [32]. Remission was defined
as inactive disease reflected in a MWS-DAS ≤5 plus
normalized CRP and SAA.
Inflammatory markers
Standardized laboratory testing was performed at each
visit and included ESR, CRP, total white blood count
(WBC), neutrophil count, hemoglobin (HGB), platelet
count (PLT), SAA, and S100A12. The latter was deter-
mined in patient sera by a double sandwich enzyme-linked
immunosorbent assay (ELISA) system, as described
previously [34].
Study end points and outcome
The primary study end points (short-term end points)
were day 14 of anakinra and day 8 of canakinumab ther-
apy, based on the distinct pharmacokinetics of each IL-1-
blocking drug. Long-term end point was the patient’s last
follow-up visit. All patients were treated with either ther-
apy until last follow-up. Treatment efficacy was measured
at each end point, including the percentage of patients
achieving remission, clinical disease activity as deter-
mined by MWS-DAS, and inflammatory markers. Treat-
ment safety was recorded and included mild and severe
infections; the latter was defined as requiring hospitaliza-
tion, injection-site reactions, and all other possible
adverse events.
Analysis
Baseline characteristics were compared by using descrip-
tive statistics. Means and standard deviations, or medians
and ranges, for nonparametric variables, were reported.
Student t test was used for continuous parametric vari-
ables, and c2 and Fisher exact test for categoric variables.
The paired t test was used for parametric variables, and
Wilcoxon signed-rank test for nonparametric repeated
measurements on single samples. Correlations were ana-
lyzed by using the Spearman rho test. All P values less
than 0.05 were considered significant. All analyses were
performed by using SAS for Windows, version 9.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Patients
In total, 21 patients with the clinical diagnosis of MWS
and confirmatory evidence of a NLRP3 mutation were
screened for inclusion into the study. Patients came
from four different families. Nine were males and 12,
females. All patients were Caucasians. The median age
at diagnosis of MWS was 33.5 (range, 3.0 to 72.0 years).
Six patients were 18 years of age or older.
Anakinra cohort
Eight patients did not meet the inclusion criteria
because of minimally active disease. One patient was
receiving dialysis and was excluded.
Canakinumab cohort
Four patients were excluded because of dialysis (one),
multiple sclerosis (one), immunosuppression after renal
transplant (one), and colon cancer (one). Three patients
did not consent to canakinumab therapy.
Baseline demographics
Anakinra cohort
In total, 12 patients (three males and nine females) were
included, of whom seven were adults, and five, children.
The median age was 19.0 years (range, 3.0 to 65.5 years) at
MWS diagnosis and 21.0 years (range, 3.0 to 66.5 years) at
start of anakinra therapy. Three different NLRP3 gene
mutations were found. Seven (58%) patients carried the
E311K mutation. The remaining mutations included T348
M in three (25%) and V198M in two (17%) patients. Med-
ian follow-up at the long-term end point was 52 months
(range, 23 to 115 months). All patients had severe MWS
(MWS-DAS ≥10).
Canakinumab cohort
In total, 14 patients (five males and nine females) were
included, of whom eight were adults, and six, children.
The median age was 27.0 years (range, 3.0 to 72.0
years) at MWS diagnosis and 29.0 years (range, 4.0 to
74.5 years) at onset of canakinumab therapy. NLRP3
gene mutations were E311K in 10 (71%), T348 M in
two (14%), and V198M in two (14%) patients. Median
follow-up at the long-term end point was 50 months
(range, 23 to 110 months). The MWS disease activity
at diagnosis was severe in 10 (71%) and mild in four
(29%).
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Rollover The 10 patients with severe disease at diagnosis
had previously received anakinra. These were two males
and eight females with a median age of 20.0 years (4.0 to
47.2 years) at the start of canakinumab therapy. Five of the
10 patients were children. Three children switched to
canakinumab for secondary treatment failure despite ana-
kinra dose escalation and excellent treatment adherence.
The mutations seen in these were E311K in one and
V198M in two children. The remaining two children and
five adult rollover patients started canakinumab for perso-
nal preference. The NLRP3 gene mutations were E311K in
six (60%), T348 M in two (20%), and V198M in two
patients (20%). The mutations of the rollover children
were V198M in two and E311K in one. All 10 had severe
disease activity at the time of treatment initiation.
Disease activity
At baseline, the mean MWS-DAS was 13 in the anakinra
cohort, reflecting severe disease. At the primary study end
point, the MWS-DAS decreased significantly to 3 (P <
0.001). At the last follow-up, the mean MWS-DAS was 4,
which is still significantly decreased when compared with
baseline (P < 0.001). The canakinumab cohort had a mean
MWS-DAS of 6 at baseline, which significantly decreased
to 3 at the primary end point (P = 0.002). At last follow-
up, the mean disease activity further decreased to 2,
remaining significantly reduced from baseline (P < 0.001).
Inflammatory markers
Anakinra cohort
At baseline, 92% had abnormal CRP and SAA levels. ESR
was elevated in 75%; 55% had elevated S100A12 levels,
including one patient with high clinical disease activity
but normal CRP and SAA levels. At 14 days of anakinra
therapy, the mean ESR decreased significantly from 9 at
baseline to 1 mm/hour (P = 0.02). The mean S100A12
levels were statistical significantly lower than at baseline
(P = 0.05). At last follow-up, ESR, CRP, and SAA levels
were significantly lower than at baseline (all P < 0.01). In
contrast, the mean S100A12 level increased, in parallel to
the mild increase in disease activity measured by MWS-
DAS. All data are summarized in Table 2.
Canakinumab cohort
At baseline, 86% of the patients had elevated CRP, and
64% had increased SAA levels; 71% had elevated
S100A12 levels, and a high ESR was seen in 64%. All
patients with raised SAA also had elevated CRP levels. At
the primary end point, none of the patients had CRP or
ESR abnormalities (P < 0.01); one continued to have
abnormal SAA (P = 0.01) and S100A12 levels (P = 0.01).
At last follow-up, mean inflammatory marker levels
remained normal in the majority of patients (ESR, CRP,
and SAA in 93% and S100A12 in 86%). All levels except
SAA were statistically significantly lower than baseline.
All results are summarized in Table 2.
Comparison of canakinumab and anakinra
Both anti-IL-1 regimens were efficacious in controlling
clinical and laboratory disease activity. The short-term
response rates for both treatments were excellent.
Anakinra-treated patients had high clinical baseline dis-
ease-activity scores, which were significantly improved
at the primary end point (P = 0.0005). In contrast,
patients receiving canakinumab had overall lower base-
line MWS-DAS scores. The mean disease activity simi-
larly significantly improved (P = 0.002), including in
patients previously treated with anakinra. Inflammatory
markers improved with both treatment regimens.
Patients treated with canakinumab had a sustained
improvement at last follow-up (see Table 2). S100A12
levels over the course of the study period are depicted
in Figure 1.
A total of 67% of anakinra-treated patients achieved clini-
cal and laboratory remission and had no evidence of active
disease at day 14; 75% remained in remission at the long-
term study end point. Three of the five pediatric patients
required dose escalation, whereas none of the adult patients
did. In canakinumab-treated patients, disease remission was
documented in 93% at both study end points. No detectable
difference in treatment efficacy was found when comparing
IL-1-blockade naïve and rollover patients treated with cana-
kinumab. Within the rollover group, those treated for
secondary treatment failure to anakinra and those switched
for personal preference also had a similar canakinumab-
treatment effect. In addition, in children and adults, canaki-
numab therapy was effective. One patient not achieving
remission at last follow-up was an adult.
Treatment safety
Anakinra cohort
No serious adverse events were observed. Mild adverse
events included injection-site reactions in five (42%) as
well as weight gain of ≥5 kg and mild upper respiratory
infections in four (33%) patients, respectively.
Canakinumab cohort
One patient developed vertigo, which was considered a
serious adverse event because of the requirement for
hospital admission. The vertigo self-resolved, and the
patient continued on canakinumab therapy. No injec-
tion-site reactions were seen. Mild upper respiratory
tract symptoms were recorded in four (29%) and transi-
ent headache in two (14%).
Discussion
The study evaluated the short- and long-term efficacy of
two distinct regimens of IL-1 blockade in pediatric and
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adult MWS patients with active disease. The high dis-
ease activity at baseline, as measured by the MWS-DAS
score, the inflammatory markers ESR, CRP, SAA, and
the neutrophil activation marker S100A12 was signifi-
cantly reduced by both IL-1-inhibiting regimens.
Ninety-three percent of canakinumab-treated patients
achieved remission at the short-term and the long-term
end points. Canakinumab led to a statistically significant
reduction of CRP, ESR, SAA, and S100A12 levels into the
normal range. The clinical disease activity decreased
further at last follow-up, indicating stable and sustained
remission. Canakinumab had an excellent safety profile
in this study, in agreement with efficacy and safety data
recently documented in CAPS patients [24,35].
Sixty-seven percent of anakinra-treated patients
achieved remission at the short-term end point, and 75%,
at the long-term study evaluation. Only ESR and S100A12
levels decreased significantly at 2 weeks, paralleling the
MWS-DAS at this study end point. However, at last fol-
low-up, the disease activity increased slightly, mirroring
the increase in S100A12 levels in some patients. In con-
trast, mean CRP, ESR, and SAA further decreased. The
anakinra safety profile was good. However, injection-site
reactions were a major complaint, similar to other reports
[15].
Disease activity in MWS is best captured when combin-
ing clinical and laboratory parameters. Our study used the
MWS-DAS to determine clinical disease activity. The mea-
sure was responsive to change after anti-IL-1 treatment.
Inflammatory markers mirrored MWS disease activity.
With clinical improvement ESR, CRP, SAA, and S100A12
levels decreased. ESR is a widely available test and has been
used in previous anti-IL-1 treatment studies [15,23]. CRP
and SAA are increasingly used at international centers to
monitor the course of diseases of the innate immune sys-
tem. Both have been found to be sensitive markers of
active FMF [36]. SAA is a predictive marker for poor out-
come in patients with amyloidosis. Lachmann [16] calcu-
lated a fivefold increased risk of death associated with high
SAA levels. S100A12 was shown to be overexpressed at
sites of local inflammation [37]. The neutrophil activation
marker was found at very high levels in sJIA and FMF [20].
In sJIA patients with inactive disease, increasing S100A12
levels indicated flares as early as weeks before becoming
clinically apparent [19].
The study had several limitations. Overall, it included
only a small number of children and adults with MWS.
However, this is one of the largest prospective cohorts of
MWS patients published to date, in whom four laboratory
parameters and standardized clinical disease-activity mea-
sures were systematically studied while monitoring two
distinct anti-IL-1 treatment regimens. The study was not a
randomized controlled trial. The study design and the
inclusion of rollover patients included a high risk for con-
founding by indication. Overall disease activity was signifi-
cantly higher in the anakinra cohort compared with the
canakinumab cohort at baseline. The study included treat-
ment-naïve and pretreated patients, some of whom only
had a partial response to initial anti-IL-1 therapy, despite
dose escalation. We documented that these patients, who
were then considered secondary treatment failures to ana-
kinra, responded well to canakinumab.
Conclusions
IL-1-blocking therapies led to a significant clinical
improvement and normalization of inflammatory markers
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Table 2 Treatment efficacy of anakinra and canakinumab in patients with MWS

















Disease activity score (MWS-DAS)
Mean MWS-DAS
(stdv)




32 (17) 13 (16) 0.02 10 (5) 0.0005 24 (9.8) 11.9 (4.6) <0.0001 8.4 (4.8) <0.0001
Elevated ESR (%)
(>22 mm/h)
9 (75) 1 (8) - 1 (8) - 9 (64) 0 1 (7)
Mean CRP in
mg/dl (stdv)
2.1 (1.3) 0.9 (1.9) 0.09 NS 0.4 (0.5) 0.0005 2.3 (2.1) 0.1 (0.1) 0.001 0.2 (0.3) 0.001
Elevated CRP (%)
(>0.5 mg/dl)





27.5 (70.5) 0.67 NS 6.6 (5.2) 0.001 88.4
(185.1)
3.4 (3.8) 0.01 4.50 (5.8) 0.11 NS
Elevated SAA (%)
(>10 mg/L)






















6/11 (55) - 5/11 (45) - 10 (71) 1 (7) - 2 (14) -
Remission (MWS-DAS ≤5 plus normal CRP and SAA)
Patients in
remission (%)
NA 8 (67) 9 (75) NA 13 (93) 13 (93)
Stdv, standard deviation. aShort-term end point was 14 days for anakinra and 8 days for canakinumab, based on the specific pharmacokinetic features of each drug. bMedian long-term end point was 12 (5 to 14)


















in the majority of MWS patients. All but one patient trea-
ted with canakinumab achieved complete and sustained
remission, whereas one fourth of anakinra-treated patients
demonstrated features of subclinical inflammatory activity
returning at last follow-up. We suggest that switching to
canakinumab after secondary failure to anakinra may be a
therapeutic option in MWS.
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and canakinumab (anti-IL-1b). Serum S100A12 levels were measured
in MWS patients treated with anakinra (IL-1Ra) at baseline (IL-1Ra bl)
and at the short-term end point (IL-1Ra d14) and at last follow-up
(IL-1Ra lfup). Similarly levels were determined in patients treated with
canakinumab (anti-IL-1b) at baseline (anti-IL-1b bl) and at the short-
term end point (anti-IL-1b d8) and at last follow-up (anti-IL-1b lfup).
Box plot depicts median, mean (dashed line), 25th and 75th percentiles
(box) and 10th and 90th percentiles. S100A12 levels are reduced by
anakinra both at short- and long-term end points. Treatment with
canakinumab reduced S100A12 levels even further and below the
limits of normal (red dashed line).
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